Mendus announces ethics committee approval for the AMLM22-CADENCE trial with lead product vididencel in AML

What we doOur approachPipelineTechnologyPatient Stories
About usManagementBoardClinical Advisory BoardCareers
Newsroom
InvestorsPress releases

Back
Mendus announces ethics committee approval for the AMLM22-CADENCE trial with lead product vididencel in AML
 8:00:00 AM

Keep reading
Mendus raises approximately SEK 69.1 million through the warrants of series TO3Read